Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others. The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia. Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions. The treatment of tardive dyskinesia is directly affect the neurological system of the respective patients. This disorder may commonly occurs in smoker than non-smoker, and also in the patient of depression, anxiety disorder and others.
This report contains market size and forecasts of Tardive Dyskinesia (TD) Treatment Drugs in Global, including the following market information:
Global Tardive Dyskinesia (TD) Treatment Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Tardive Dyskinesia (TD) Treatment Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Valbenazine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tardive Dyskinesia (TD) Treatment Drugs include Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries, Pfizer Inc., Biogen, Novartis AG, AstraZeneca, GlaxoSmithKline plc., Bayer AG and Sanofi. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tardive Dyskinesia (TD) Treatment Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tardive Dyskinesia (TD) Treatment Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Tardive Dyskinesia (TD) Treatment Drugs Market Segment Percentages, by Type, 2021 (%)
Valbenazine
Deutetrabenazine
Global Tardive Dyskinesia (TD) Treatment Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Tardive Dyskinesia (TD) Treatment Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinic
Others
Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Tardive Dyskinesia (TD) Treatment Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tardive Dyskinesia (TD) Treatment Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Tardive Dyskinesia (TD) Treatment Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries
Pfizer Inc.
Biogen
Novartis AG
AstraZeneca
GlaxoSmithKline plc.
Bayer AG
Sanofi